MicroRNA‑125a‑3p downregulation correlates with tumorigenesis and poor prognosis in patients with non‑small cell lung cancer

Hou,Likun; Luo,Pei; Ma,Yushui; Jia,Chengyou; Yu,Fei; Lv,Zhongwei; Wu,Chunyan; Fu,Da

doi:10.3892/ol.2017.6809

MicroRNA‑125a‑3p downregulation correlates with tumorigenesis and poor prognosis in patients with non‑small cell lung cancer

Authors:
- Likun Hou
- Pei Luo
- Yushui Ma
- Chengyou Jia
- Fei Yu
- Zhongwei Lv
- Chunyan Wu
- Da Fu
View Affiliations

Affiliations: Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P.R. China, Veterinary Faculty, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, P.R. China, Department of Nuclear Medicine, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: August 24, 2017 https://doi.org/10.3892/ol.2017.6809
Pages: 4441-4448
Copyright: © Hou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑125a‑3p is derived from the 3'‑end of pre‑miR‑125a, which is associated with several types of cancer, such as gastric and prostate cancer, and glioma. The aim of the present study was to identify the prognostic significance of miR‑125a‑3p expression levels in patients with NSCLC. The gene expression omnibus database was used to analyze miR‑125a‑3p expression in NSCLC in silico, and 148 NSCLC samples and 30 adjacent normal lung tissue specimens were analyzed for the expression of miR‑125a‑3p by qPCR. The results showed that the expression levels of miR‑125a‑3p in the adjacent normal tissues was higher than the expression level in the NSCLC tissues. There were several clinical parameters demonstrated to be associated with miR‑125a‑3p expression, such as lymph node metastasis, tumor node metastasis classification of malignant tumor stage and tumor diameter. Furthermore, high expression levels of miR‑125a‑3p with chemotherapy prolonged the overall survival rate and disease free survival rate compared with untreated patients with low expression of miR‑125a‑3p. Thus, miR‑125a‑3p is a significant prognostic biomarker for patients with NSCLC, from which a novel therapeutic strategy to combat NSCLC may be derived.

View Figures

View References

1	Han Y, Jia C, Cong X, Yu F, Cai H, Fang S, Cai L, Yang H, Sun Y, Li D, et al: Increased expression of TGFβR2 is associated with the clinical outcome of non-small cell lung cancer patients treated with chemotherapy. PLoS One. 10:e01346822015. View Article : Google Scholar : PubMed/NCBI
2	Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H, et al: MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res. 19:5423–5433. 2013. View Article : Google Scholar : PubMed/NCBI
3	Mitra R, Edmonds MD, Sun J, Zhao M, Yu H, Eischen CM and Zhao Z: Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer. RNA. 20:1356–1368. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zhang L, Wang XF, Ma YS, Xia Q, Zhang F, Fu D and Wang YC: Quantitative assessment of the influence of TP63 gene polymorphisms and lung cancer risk: Evidence based on 93,751 subjects. PLoS One. 9:e870042014. View Article : Google Scholar : PubMed/NCBI
5	Shen S, Yue H, Li Y, Qin J, Li K, Liu Y and Wang J: Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumor Biol. 35:631–640. 2014. View Article : Google Scholar
6	Fang Y, Fu D and Shen XZ: The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta. 1806:1–6. 2010.PubMed/NCBI
7	Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, Martin-Subero JI, Cordeu L, Gárate L, José-Eneriz San E, Abizanda G, Rodríguez-Otero P, Fortes P, et al: Epigenetic silencing of the tumor suppressor microRNA hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69:4443–4453. 2009. View Article : Google Scholar : PubMed/NCBI
8	Pierson J, Hostager B, Fan R and Vibhakar R: Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 90:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
9	Li JQ, Hu SY, Wang ZY, Lin J, Jian S, Dong YC, Wu XF, Lan D and Cao LJ: MicroRNA-125-5p targeted CXCL13: A potential biomarker associated with immune thrombocytopenia. Am J Transl Res. 15:772–780. 2015.
10	Xie J, Yu F, Li D, Zhu X, Zhang X and Lv Z: MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumor Biol. 37:1197–1204. 2016. View Article : Google Scholar
11	Zhou YL, Xu YJ and Qiao CW: miR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp Pathol. 8:6312–6322. 2015.PubMed/NCBI
12	Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D and Chen J: The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia. 17:239–255. 2015. View Article : Google Scholar : PubMed/NCBI
13	Hashiguchi Y, Nishida N, Mimori K, Sudo T, Tanaka F, Shibata K, Ishii H, Mochizuki H, Hase K, Doki Y and Mori M: Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol. 40:1477–1482. 2012.PubMed/NCBI
14	Ruike Y, Ichimura A, Tsuchiya S, Shimizu K, Kunimoto R, Okuno Y and Tsujimoto G: Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines. J Hum Genet. 53:515–523. 2008. View Article : Google Scholar : PubMed/NCBI
15	Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion. Acta Biochim Biophys Sin (Shanghai). 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
16	Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H and Beer DG: MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 69:5776–5783. 2009. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X and Wang E: hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer. 10:3182010. View Article : Google Scholar : PubMed/NCBI
19	Li W, Duan R, Kooy F, Sherman SL, Zhou W and Jin P: Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet. 46:358–360. 2008. View Article : Google Scholar
20	Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, et al: Ectopic expression of miR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012. View Article : Google Scholar : PubMed/NCBI
21	Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J and Lin T: MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer. 128:1758–1769. 2011. View Article : Google Scholar : PubMed/NCBI
22	Tong Z, Liu N, Lin L, Guo X, Yang D and Zhang Q: miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1. Biomed Pharmacother. 75:129–136. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N, Tuvar A, Chuderland D, Stemmer SM, Ben-Aharon I and Shalgi R: MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience. 1:250–261. 2014. View Article : Google Scholar : PubMed/NCBI
24	Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H and Ochiai A: MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers. PLoS One. 10:e01182202015. View Article : Google Scholar : PubMed/NCBI
25	Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, Kondo S and Hashimoto H: Identification of altered microRNA expression patterns in synovial sarcoma. Genes Chromosomes Cancer. 50:137–145. 2011. View Article : Google Scholar : PubMed/NCBI
26	Della VittoriaScarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S and Pepe S: A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar : PubMed/NCBI
27	Chonglei Bi, Chung TH, Huang G, Zhou J, Yan J, Gregory JA, Fonseca R and Chng WJ: Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 6:26508–26518. 2015. View Article : Google Scholar : PubMed/NCBI
28	Xu X, Jia R, Zhou Y, Song X, Wang J, Qian G, Ge S and Fan X: Microarray-based analysis: Identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 38:1385–1393. 2011.PubMed/NCBI
29	Jiang L, Chang J, Zhang Q, Sun L and Qiu X: MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells. Cancer Invest. 31:538–544. 2013. View Article : Google Scholar : PubMed/NCBI
30	Zhou DH, Wang X and Feng Q: EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. Nutr Cancer. 66:636–644. 2014. View Article : Google Scholar : PubMed/NCBI
31	Huang B, Luo W, Sun L, Zhang Q, Jiang L, Chang J, Qiu X and Wang E: miRNA-125a-3p is a negative regulator of the RhoA-actomyosin pathway in A549 cells. Int J Oncol. 42:1734–1742. 2013. View Article : Google Scholar : PubMed/NCBI
32	Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration and invasion. Acta Biochim Biophys Sin (Shanghai). 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
33	Li M, Zhang Q, Wu L, Jia C, Shi F, Li S, Peng A, Zhang G, Song X and Wang C: Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer. Oncol Rep. 31:1961–1967. 2014.PubMed/NCBI
34	Zhou DH, Wang X and Feng Q: EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. Nutr Cancer. 66:636–644. 2014. View Article : Google Scholar : PubMed/NCBI
35	Xu FX, Su YL, Zhang H, Kong JY, Yu H and Qian BY: Prognostic implications for high expression of miR-25 in lung adenocarcinomas of female non-smokers. Asian Pac J Cancer Prev. 15:1197–1203. 2014. View Article : Google Scholar : PubMed/NCBI
36	Xu T, Liu X, Han L, Shen H, Liu L and Shu Y: Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol. 16:469–475. 2013. View Article : Google Scholar : PubMed/NCBI
37	Wang M, Zhang Q, Wang J and Zhai Y: MicroRNA-498 is downregulated in non-small cell lung cancer and correlates with tumor progression. J Cancer Res Ther. 11 Suppl 1:S107–S111. 2015. View Article : Google Scholar